Announcement • Apr 17
DocMorris AG, Annual General Meeting, May 12, 2026 DocMorris AG, Annual General Meeting, May 12, 2026, at 17:00 W. Europe Standard Time. Reported Earnings • Mar 19
Full year 2025 earnings released: CHF3.47 loss per share (vs CHF8.25 loss in FY 2024) Full year 2025 results: CHF3.47 loss per share. Revenue: CHF1.13b (up 11% from FY 2024). Net loss: CHF134.4m (loss widened 38% from FY 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Consumer Retailing industry in the United Kingdom. New Risk • Jan 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (277% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF28m net loss in 3 years). Share price has been volatile over the past 3 months (7.0% average weekly change). Reported Earnings • Aug 20
Second quarter 2025 earnings released: CHF0.78 loss per share (vs CHF0.81 loss in 2Q 2024) Second quarter 2025 results: CHF0.78 loss per share. Revenue: CHF265.2m (up 5.3% from 2Q 2024). Net loss: CHF36.3m (loss widened 25% from 2Q 2024). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Consumer Retailing industry in the United Kingdom. Announcement • May 23
DocMorris AG has completed a Follow-on Equity Offering in the amount of CHF 208.051043 million. DocMorris AG has completed a Follow-on Equity Offering in the amount of CHF 208.051043 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 36,182,790
Price\Range: CHF 5.75
Transaction Features: Rights Offering Announcement • May 22
DocMorris AG announced that it expects to receive funding from Pelion S.A. DocMorris AG announced that it will receive Funding from the new investor, Pelion S.A. for 9.68% stake in the company on May 20, 2025. The company will issue New Risk • May 22
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 285% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF93m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Shareholders have been substantially diluted in the past year (285% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CHF26m net loss in 3 years). Reported Earnings • May 09
First quarter 2025 earnings released: CHF2.13 loss per share (vs CHF0.75 loss in 1Q 2024) First quarter 2025 results: CHF2.13 loss per share (further deteriorated from CHF0.75 loss in 1Q 2024). Revenue: CHF282.6m (up 14% from 1Q 2024). Net loss: CHF25.2m (loss widened 185% from 1Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings. Board Change • May 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Non-Executive Independent Director Rongrong Hu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Apr 15
DocMorris AG, Annual General Meeting, May 08, 2025 DocMorris AG, Annual General Meeting, May 08, 2025, at 17:00 W. Europe Standard Time. Announcement • Apr 11
DocMorris AG Provides Earnings Guidance for the Year 2025 DocMorris AG provided earnings guidance for the year 2025. For the year, the company expects external revenues growth of more than 10%. Reported Earnings • Mar 14
First half 2024 earnings released: CHF3.22 loss per share (vs CHF4.99 loss in 1H 2023) First half 2024 results: CHF3.22 loss per share (improved from CHF4.99 loss in 1H 2023). Revenue: CHF496.3m (up 7.2% from 1H 2023). Net loss: CHF37.9m (loss narrowed 35% from 1H 2023). Revenue is forecast to grow 14% p.a. on average during the next 4 years, compared to a 3.4% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings. Breakeven Date Change • Mar 13
No longer forecast to breakeven The 10 analysts covering DocMorris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF4.08m in 2027. New consensus forecast suggests the company will make a loss of CHF22.5m in 2027. New Risk • Jan 17
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CHF17m net loss in 3 years). Reported Earnings • Aug 23
First half 2024 earnings released: CHF3.22 loss per share (vs CHF4.99 loss in 1H 2023) First half 2024 results: CHF3.22 loss per share (improved from CHF4.99 loss in 1H 2023). Revenue: CHF496.3m (up 7.2% from 1H 2023). Net loss: CHF37.9m (loss narrowed 35% from 1H 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. Breakeven Date Change • Aug 23 The 12 analysts covering DocMorris previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 38% per year to 2025. The company is expected to make a profit of CHF8.95m in 2026. Average annual earnings growth of 69% is required to achieve expected profit on schedule.
New Risk • Aug 22
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CHF97m Forecast net loss in 3 years: CHF387k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10.0% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF387k net loss in 3 years). Shareholders have been diluted in the past year (9.5% increase in shares outstanding). New Risk • Aug 20
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-CHF115m). Shareholders have been diluted in the past year (9.5% increase in shares outstanding). Announcement • Jun 20
DocMorris AG to Report Q3, 2025 Results on Oct 16, 2025 DocMorris AG announced that they will report Q3, 2025 results on Oct 16, 2025 New Risk • May 03
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-CHF115m). Share price has been volatile over the past 3 months (8.0% average weekly change). Shareholders have been diluted in the past year (8.1% increase in shares outstanding). Reported Earnings • Mar 24
Full year 2023 earnings released: CHF10.07 loss per share (vs CHF15.88 loss in FY 2022) Full year 2023 results: CHF10.07 loss per share (improved from CHF15.88 loss in FY 2022). Revenue: CHF969.5m (up 4.1% from FY 2022). Net loss: CHF117.6m (loss narrowed 31% from FY 2022). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. New Risk • Mar 22
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.3% per year for the foreseeable future. Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change). New Risk • Oct 10
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CHF146m Forecast net loss in 3 years: CHF852k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF852k net loss in 3 years). Share price has been volatile over the past 3 months (7.4% average weekly change). New Risk • Aug 28
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CHF146m Forecast net loss in 3 years: CHF344k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF344k net loss in 3 years). Share price has been volatile over the past 3 months (10.0% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding). Reported Earnings • Aug 20
First half 2023 earnings released: CHF4.99 loss per share (vs CHF8.05 loss in 1H 2022) First half 2023 results: CHF4.99 loss per share (improved from CHF8.05 loss in 1H 2022). Revenue: CHF463.0m (down 6.4% from 1H 2022). Net loss: CHF58.2m (loss narrowed 30% from 1H 2022). Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings. Announcement • May 05
Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE). Medbase AG agreed to acquire Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023. The proceeds from the sale of approximately CHF 360 million in cash comprise a first tranche upon completion of the transaction, expected in the second quarter of 2023, and an earnout of CHF 47 million based on the achievement of Zur Rose Switzerland's 2023 EBITDA target, payable in the second quarter of 2024. Zur Rose Switzerland achieved revenue of CHF 687 million in 2022.The transaction is expected to close in the second quarter of 2023, subject to approval by the competition authority. As on April 28, 2023 Competition commission validated the transaction. Matthias Courvoisier, Olha Demianiuk, Yves Mauchle, Beau Visser, Roger Thomi, Bettina Klein, Victoria Brammer and Victoria Hotz of Baker & McKenzie (Zurich) acted as legal advisor to Zur Rose Group AG. Morgan Stanley (NYSE:MS) and Enqcor AG acted as financial advisor to Zur Rose Group AG (SWX:ROSE).Bär & Karrer Ltd. acted as legal advisor to Medbase AG .
Medbase AG completed the acquisition of Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on May 4, 2023. Medbase is taking over all the Zur Rose Group's operational units in Switzerland excluding land and properties with all employees. Announcement • Feb 03
Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE). Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023.Medbase AG completed the acquisition of Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023. Reported Earnings • Aug 19
First half 2022 earnings released: CHF8.29 loss per share (vs CHF8.03 loss in 1H 2021) First half 2022 results: CHF8.29 loss per share (down from CHF8.03 loss in 1H 2021). Revenue: CHF840.3m (flat on 1H 2021). Net loss: CHF86.1m (loss widened 12% from 1H 2021). Over the next year, revenue is forecast to grow 15%, compared to a 5.8% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Breakeven Date Change • Dec 23
No longer forecast to breakeven The 8 analysts covering Zur Rose Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF16.8m in 2023. New consensus forecast suggests the company will make a loss of CHF2.23m in 2023. Breakeven Date Change • Sep 23
Forecast to breakeven in 2023 The 9 analysts covering Zur Rose Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CHF22.7m in 2023. Average annual earnings growth of 62% is required to achieve expected profit on schedule. Reported Earnings • Aug 21
First half 2021 earnings released: CHF8.03 loss per share (vs CHF6.03 loss in 1H 2020) The company reported a soft first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: CHF839.8m (up 20% from 1H 2020). Net loss: CHF77.0m (loss widened 47% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has increased by 35% per year, which means it is well ahead of earnings. Breakeven Date Change • Jun 13
No longer forecast to breakeven The 9 analysts covering Zur Rose Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF16.8m in 2023. New consensus forecast suggests the company will make a loss of CHF14.2m in 2023. Executive Departure • May 04
Non-Executive Director has left the company On the 29th of April, Tobias Hartmann's tenure as Non-Executive Director ended after 1.9 years in the role. As of December 2020, Tobias personally held 394.00 shares (CHF110k worth at the time). Tobias is the only executive to leave the company over the last 12 months. Reported Earnings • Apr 10
Full year 2020 earnings released: CHF14.95 loss per share (vs CHF6.04 loss in FY 2019) The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CHF1.48b (up 9.0% from FY 2019). Net loss: CHF135.7m (loss widened 159% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 48% per year, which means it is well ahead of earnings. Reported Earnings • Mar 20
Full year 2020 earnings released The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CHF1.48b (up 9.0% from FY 2019). Net loss: CHF135.6m (loss widened 159% from FY 2019). Is New 90 Day High Low • Feb 07
New 90-day high: CHF465 The company is up 71% from its price of CHF273 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF1,030 per share. Is New 90 Day High Low • Jan 22
New 90-day high: CHF410 The company is up 74% from its price of CHF235 on 23 October 2020. The British market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 10.0% over the same period. Is New 90 Day High Low • Jan 05
New 90-day high: CHF286 The company is up 27% from its price of CHF226 on 07 October 2020. The British market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Dec 07
New 90-day low: CHF124 The company is down 42% from its price of CHF213 on 08 September 2020. The British market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Nov 07
New 90-day low: CHF124 The company is down 53% from its price of CHF262 on 07 August 2020. The British market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF31.15 per share. Announcement • Aug 19
Zur Rose Group AG to Report Fiscal Year 2020 Results on Mar 18, 2021 Zur Rose Group AG announced that they will report fiscal year 2020 results on Mar 18, 2021 Announcement • Aug 18
Zur Rose Group AG (SWX:ROSE) completed the acquisition of AdBest Werbeagentur GmbH, Ultra Pharm Medicalprodukte Gmbh and Dia Plus Minus Handelsgesellschaft mbH from apotal.de. Zur Rose Group AG (SWX:ROSE) agreed to acquire AdBest Werbeagentur GmbH, Ultra Pharm Medicalprodukte Gmbh and Dia Plus Minus Handelsgesellschaft mbH from apotal.de on June 26, 2020. AdBest Werbeagentur GmbH, Ultra Pharm Medicalprodukte Gmbh and Dia Plus Minus Handelsgesellschaft mbH formed the Mail-order and Diabetes Activities of Apotal Group. The acquisition is financed from available cash and up to 60% of the purchase price by issuing new shares funded from the authorized and conditional capital. As part of the transaction, Heinz-Peter Fichter will become a shareholder and future consultant of Zur Rose Group, Henning Fichter will be the managing director of the diabetes division and 1.1 million active customers will be transferred to Zur Rose subject to giving their consent. The transaction is subject to approval by the German Federal Cartel Office and expected to close in third quarter of 2020.
Johannes H. Lucas of ACXIT Capital Partners acted as financial advisor to Zur Rose. Klaus Krink, Sönke Storch, Björn Schallock, Albrecht von Bismarck, Jörn Karall and Stephan Weber of Ebner Stolz acted as legal advisor and Alvarez & Marsal Securities, LLC provided due diligence to Zur Rose. Christoph Smile, Jochen Lux, Boris Alles, Heralt Hug, Jörn Witt, Susanne Pech, Dirk Schauer, Martin Mohr and Rolf Hempel of CMS Germany and Daniel Jenny of CMS Switzerland acted as legal advisor to Heinz-Peter Fichter, founder of Apotal Group and other partners. FERBER & CO. GmbH acted as financial advisor to Apotal Group and Heinz-Peter Fichter. Clemens Krämer of Dorn Krämer & Partner acted as legal advisor for Zur Rose.
Zur Rose Group AG (SWX:ROSE) completed the acquisition of AdBest Werbeagentur GmbH, Ultra Pharm Medicalprodukte Gmbh and Dia Plus Minus Handelsgesellschaft mbH from apotal.de on August 17, 2020. For payment of the share portion of the purchase price, Zur Rose issued 0.13 million shares. 
